Physician profile
Robert L Shackleton
NPI 1689601254
$1,446.57
in general payments reported to CMS, 2019-2025
24 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $160 · 2021: $96.74 · 2022: $175 · 2023: $295 · 2024: $278 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $252.34 | 2022-2025 | Triathlon, Gamma, Tornier Perform Reversed Glenoid |
| Pacira Therapeutics, INC. | $182.62 | 2019-2021 | |
| Globus Medical, INC. | $152.70 | 2023-2024 | Trauma Compression Screw, A/R Femoral Nail, Onvoy |
| Medacta USA, INC. | $137.19 | 2022-2023 | Amistem, Masterloc |
| Depuy Synthes Sales INC. | $106.35 | 2019-2022 | |
| Biocomposites INC | $91.28 | 2025 | Stimulan |
| Convatec INC. | $82.83 | 2024-2025 | |
| Fidia Pharma USA INC. | $47.92 | 2023-2025 | Hymovis, Triluron |
| Heron Therapeutics, INC. | $46.24 | 2023-2024 | Zynrelef |
| Amgen INC. | $41.97 | 2019-2020 | |
| Bone Support INC. | $35.56 | 2025 | Ceramentbone Void Filler, Cerament G |
| Ferring Pharmaceuticals INC. | $31.15 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.67 | 2022 | |
| Kerecis Limited | $26.20 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Collegium Pharmaceutical, INC. | $24.78 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vericel Corporation | $24.70 | 2024 | Maci |
| Smith+Nephew, INC. | $21.97 | 2024 | Pico 14 |
| Ermi LLC | $21.05 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.23 | 2019 | |
| Baudax Bio INC. | $16.97 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.67 | 2023 | Zilretta, Iovera, Exparel |
| Medtronic, INC. | $15.40 | 2021 | |
| Esaote North America, INC. | $15.15 | 2025 | |
| Trevena, INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shackleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.